Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 2
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

3 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB; DEVOTE Study Group. Marso SP, et al. N Engl J Med. 2017 Aug 24;377(8):723-732. doi: 10.1056/NEJMoa1615692. Epub 2017 Jun 12. N Engl J Med. 2017. PMID: 28605603 Free PMC article. Clinical Trial.
Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy.
Eigentler TK, Hassel JC, Berking C, Aberle J, Bachmann O, Grünwald V, Kähler KC, Loquai C, Reinmuth N, Steins M, Zimmer L, Sendl A, Gutzmer R. Eigentler TK, et al. Cancer Treat Rev. 2016 Apr;45:7-18. doi: 10.1016/j.ctrv.2016.02.003. Epub 2016 Feb 18. Cancer Treat Rev. 2016. PMID: 26922661 Review.
Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions.
Hassel JC, Heinzerling L, Aberle J, Bähr O, Eigentler TK, Grimm MO, Grünwald V, Leipe J, Reinmuth N, Tietze JK, Trojan J, Zimmer L, Gutzmer R. Hassel JC, et al. Cancer Treat Rev. 2017 Jun;57:36-49. doi: 10.1016/j.ctrv.2017.05.003. Epub 2017 May 18. Cancer Treat Rev. 2017. PMID: 28550712 Review.
Feedback